HAYWARD, CA – June 13, 2019 - Paragon Genomics, Inc., a leader in amplicon-based target enrichment and library preparation solutions for next-generation sequencing (NGS) assays, today announced the first availability of its CleanPlex products for use with sequencers from MGI Tech Co., Ltd. (MGI), a leading producer of high-throughput gene sequencers. Earlier this year the two companies entered into a global partnership allowing MGI to distribute CleanPlex NGS Panels optimized for use with MGI’s sequencing platforms in all territories worldwide except the U.S. The MGI CleanPlex panels will be launched at the 2019 Annual Meeting of the European Society for Human Genetics (ESHG 2019), where Paragon Genomics also has multiple poster presentations and several partner exhibitor education events.
Tao Chen, co-founder and CEO of Paragon Genomics, said, “We are committed to ensuring wide access to CleanPlex, the most advanced amplicon-based NGS target enrichment technology. It enables the accurate, fast and efficient ultra-high multiplexed genomic profiling of challenging samples in a single assay. With an installed base of more than 1,100 sequencers worldwide and robust growth, MGI users represent an increasingly important segment of the NGS market. We are pleased to launch these first assays optimized for MGI sequencers less than six months after initiating our partnership and look forward to releasing additional products on an ongoing basis.”
The launch of the MGI CleanPlex panels represents the first deliverable from the MGI-Paragon Genomics partnership launched in January, showing that “MGI certified assays” can work and integrate with MGI’s DNBSEQTM sequencers and workstations. “It is a great first step to build an open, inclusive and collaborative community around DNBSEQ NGS sequencing technology,” said Hui Jiang, COO of MGI.
MGI reports it has installed 1,100 of its sequencers in 16 countries and has more than 300 users. The new CleanPlex products for MGI sequencers include:
§ CleanPlex for MGI Ready-to-Use NGS Panels – the CleanPlex for MGI OncoZoom Cancer Hotspot Panel and CleanPlex for MGI BRCA1 and BRCA2 Panel. Both are completely compatible with MGISEQ sequencers.
§ CleanPlex for MGI Custom NGS Panels – these allow researchers to build customized assays addressing their specific needs. Paragon Genomics support staff will take custom orders and design and deliver panels that are completely compatible with MGISEQ sequencers.
§ Validated automation protocols ensuring that CleanPlex for MGI assays are compatible with the MGISP-960 Automated Sample Preparation System and produce results equivalent to those from manual operation.
MGI’s genetic sequencers, based on the company’s proprietary DNBSEQ sequencing technology, combine the power of DNA Nanoballs (DNB), PCR-free Rolling Circle Replication, Patterned Nano Arrays and cPAS to deliver a new level of data clarity and affordability.
MGISP-960 High-throughput Automated Sample Preparation System is a flexible, fully automated workstation with a built-in NGS sample-prep process and tailored workflows to satisfy the unique needs of individual labs. MGIFLP is a modular NGS workstation that integrates the entire NGS process into one step and provides clinical personnel and researchers a fully automated solution, from sample to sequencing report. The automation solutions enable MGI’s customers to optimize their NGS workflows, even with their own assays.
§ MGI is hosting a Corporate Satellite session entitled “Towards a Perfect Genome” that includes a discussion of CleanPlex technology:
o Saturday, June 15, 2019, 10:00 - 11:30 am
o Room A-3 Svenska, Massan Gothia Towers
o Presentation: CleanPlex for MGI: A New Targeted NGS Solution with Exceptional Coverage, Uniformity and Rapid Customization
o Speaker: Edward Jan, PhD, Director of Product Marketing, Paragon Genomics, Inc.
Paragon Genomics’ CleanPlex products are for Research Use Only.
About Paragon Genomics
Paragon Genomics (paragongenomics.com) is a leader in amplicon-based target enrichment and library preparation solutions to accelerate the development of next-generation sequencing (NGS)-based assays for research and clinical testing. The company designs high performance and ultra-multiplexed amplicon NGS panels and develops NGS library preparation chemistries for analyzing difficult, clinically-relevant samples. It strives to make the design of custom NGS assays easily available to a broad range of users, with expert counsel and rapid turnaround. Privately-held Paragon Genomics is located in Hayward, California.